New FDA mandate to tell patients whether their breasts are “dense” or “not dense” baffles doctors Problem: “Breast density is in the eye of the mammographer”

Charles Geyer named associate group chair of NRG Oncology

The NRG Oncology Group Chairs created the position of associate group chair and selected Charles E. Geyer to fill the position, effective immediately. He will serve alongside the three NRG Oncology group chairs, Quynh-Thu Le, Robert Mannel, and Norman Wolmark.

February 21, 2025

Vol.51 No.07

NCI study: Prevention and screening saved more lives than treatment in five common cancer types over the past half-century

Over the last 45 years, prevention and screening interventions have made a greater contribution to averting cancer deaths than have improvements in treatment, according to a modeling study led by researchers at NCI.

January 31, 2025

Vol.51 No.04

By Yiqing Wang and Jacquelyn Cobb

Clinical Roundup

Genentech’s Itovebi demonstrated OS benefit in advanced breast cancer, phase III trial finds

Genentech announced positive topline results from the overall survival analysis of the phase III INAVO120 study investigating Itovebi (inavolisib) in combination with palbociclib (Ibrance) and fulvestrant for people with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.

January 31, 2025

Vol.51 No.04

Drugs & Targets

FDA approves Enhertu as first HER2-directed therapy for breast cancer

FDA approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by the FDA approved test, that has progressed on one or more endocrine therapies in the metastatic setting.

January 31, 2025

Vol.51 No.04

Conversation with The Cancer Letter Real-world Evidence

RWD company documents baseline trends in women’s cancers before Trump’s policy changes

The U.S. Supreme Court’s June 2022 decision to overturn Roe v. Wade has implications that reach far beyond access to reproductive health care services in the 41 states that ban or restrict access to abortion.

January 24, 2025

Vol.51 No.03

By Claire Marie Porter

Clinical Roundup

SWOG study: Statistical tool provides more accurate estimates of recurrence risk and chemotherapy benefit in breast cancer

A new statistical tool that combines multiple clinical and pathologic factors with a patient’s 21-gene Oncotype DX Breast Recurrence Score result provides more accurate estimates about that patient’s breast cancer prognosis and their potential benefit from chemotherapy than either the Recurrence Score result or clinical factors alone, a SWOG Cancer Research study found.

January 24, 2025

Vol.51 No.03

New FDA mandate to tell patients whether their breasts are “dense” or “not dense” baffles doctors

Problem: “Breast density is in the eye of the mammographer”

YOU MAY BE INTERESTED IN

Charles Geyer named associate group chair of NRG Oncology

NCI study: Prevention and screening saved more lives than treatment in five common cancer types over the past half-century

Genentech’s Itovebi demonstrated OS benefit in advanced breast cancer, phase III trial finds

FDA approves Enhertu as first HER2-directed therapy for breast cancer

RWD company documents baseline trends in women’s cancers before Trump’s policy changes

SWOG study: Statistical tool provides more accurate estimates of recurrence risk and chemotherapy benefit in breast cancer

Renew today!

Subscriber content

Never miss an issue!

Login